Verrica Pharmaceuticals Inc (NASDAQ: VRCA) kicked off on Tuesday, down -6.12% from the previous trading day, before settling in for the closing price of $0.77. Over the past 52 weeks, VRCA has traded in a range of $0.38-$7.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -5.46% over the past five years. While this was happening, its average annual earnings per share was recorded 77.53%. With a float of $50.08 million, this company’s outstanding shares have now reached $91.79 million.
Let’s look at the performance matrix of the company that is accounted for 71 employees. In terms of profitability, gross margin is 71.79%, operating margin of -772.39%, and the pretax margin is -919.21%.
Verrica Pharmaceuticals Inc (VRCA) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verrica Pharmaceuticals Inc is 45.85%, while institutional ownership is 32.25%. The most recent insider transaction that took place on Mar 17 ’25, was worth 2,805. In this transaction CHIEF LEGAL OFFICER of this company sold 4,315 shares at a rate of $0.65, taking the stock ownership to the 176,458 shares. Before that another transaction happened on Aug 26 ’24, when Company’s CHIEF LEGAL OFFICER sold 26,183 for $2.66, making the entire transaction worth $69,647. This insider now owns 115,303 shares in total.
Verrica Pharmaceuticals Inc (VRCA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 77.53% per share during the next fiscal year.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Trading Performance Indicators
Take a look at Verrica Pharmaceuticals Inc’s (VRCA) current performance indicators. Last quarter, stock had a quick ratio of 1.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.20, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.24 in one year’s time.
Technical Analysis of Verrica Pharmaceuticals Inc (VRCA)
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) saw its 5-day average volume 0.37 million, a negative change from its year-to-date volume of 0.41 million. As of the previous 9 days, the stock’s Stochastic %D was 24.42%.
During the past 100 days, Verrica Pharmaceuticals Inc’s (VRCA) raw stochastic average was set at 59.89%, which indicates a significant increase from 38.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1041 in the past 14 days, which was higher than the 0.0737 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6457, while its 200-day Moving Average is $0.7645. Nevertheless, the first resistance level for the watch stands at $0.7747 in the near term. At $0.8273, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.8647. If the price goes on to break the first support level at $0.6847, it is likely to go to the next support level at $0.6473. The third support level lies at $0.5947 if the price breaches the second support level.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Key Stats
The company with the Market Capitalisation of 66.77 million has total of 92,491K Shares Outstanding. Its annual sales at the moment are 7,570 K in contrast with the sum of -76,580 K annual income. Company’s last quarter sales were recorded 3,440 K and last quarter income was -9,740 K.
